Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 3/2018

01-12-2018 | Acknowledgement

Acknowledgement of reviewers 2017

Published in: Breast Cancer Research and Treatment | Issue 3/2018

Login to get access

Excerpt

The Editor, Marc Lippman, and Associate Editors Stephen P. Ethier, Kevin S. Hughes, Alberto Montero, Steven A. Narod, and Ben H. Park would like to acknowledge the valuable contributions of the reviewers to the journal. We fully understand the burden and effort that are involved in the reviews. We rely on your expertise to maintain the standards of excellent science for Breast Cancer Research and Treatment. …
Metadata
Title
Acknowledgement of reviewers 2017
Publication date
01-12-2018
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 3/2018
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-018-4998-1

Other articles of this Issue 3/2018

Breast Cancer Research and Treatment 3/2018 Go to the issue

Epidemiology

A portrait of germline mutation in Brazilian at-risk for hereditary breast cancer

Brief Report

Epigenetic modulation of FOXM1-gene interacting network by BET inhibitors in breast cancer

Clinical trial

Only estrogen receptor “positive” is not enough to predict the prognosis of breast cancer

Rebuttal Letter

Challenge for identifying the origin of occult breast cancer for optimizing local therapy

Preclinical study

Labour productivity loss caused by premature deaths associated with breast cancer: results from Spain over a 10-year period

Letter to the Editor

Theoretical possibility of primary breast cancer originates from ectopic breast tissue in axillary lymph nodes
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits